Synapse - Nursing

Results (63)

KOS-862 (Epothilone D): Phase 1 dose escalating and pharmacokinetic (PK) study in patients (pts) with advanced malignancies

Meeting Abstract

Spriggs, D. R.; Dupont, J.; Pezzulli, S.; Larkin, J.; Cropp, G.; Zhou, Y.; Sherrill, M.; Johnson, R. Jr; Hannah, A. L.
EJC Supplements (2003)

Fulltext@MSK | Save

Immunogenicity of GD2 lactone (GD2L)-KLH conjugate plus immunological adjuvant QS-21 vaccine in patients with melanoma

Meeting Abstract

Ragupathi, G.; Livingston, P. O.; Hood, C.; Krown, S. E.; Chapman, P. B.; Wolchok, J. D.; Williams, L. J.; Oldfield, R. C.; Hwu, W. J.
Proceedings of the American Association for Cancer Research Annual Meeting (2003)

Fulltext@MSK | Save

The epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib (TarcevaTM, OSI-774), is an active agent in bronchioloalveolar carcinoma (BAC) and its variants: Interim results of a phase II trial

Meeting Abstract

Patel, J.; Miller, V.; Kris, M.; Shah, N.; Tyson, L.; Pizzo, B.; Zakowski, M.; Cespon, M.; Heelan, R.; Johnson, D.
EJC Supplements (2003)

Fulltext@MSK | Save

Phase II clinical experience with the novel proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent and mantle cell lymphomas

Meeting Abstract

O'Connor, O. A.; Wright, J.; Moskowitz, C.; Straus, D.; Macgregor-Cortelli, B.; Muzzy, J.; Choi, P.; Schenkein, D.; Zelenetz, A. D.
EJC Supplements (2003)

Fulltext@MSK | Save

Phase I trial to evaluate J591 as a vascular targeting agent in patients with advanced solid tumors

Meeting Abstract

Morris, M. J.; Divgi, C.; Kelly, W. K.; Slovin, S.; Solit, D.; Shaffer, D.; Halpern, J.; Delacruz, A.; Curley, T.; Nacca, A.; more...
Proceedings of the American Association for Cancer Research Annual Meeting (2003)

Fulltext@MSK | Save

Phase I study of HSPPC-96 (Oncophage(R)) vaccine in patients with completely resected pancreatic adenocarcinoma

Meeting Abstract

Maki, R. G.; Lewis, J. J.; Janetzki, S.; Klimstra, D.; Desantis, D.; Hirst, C.; Houghton, A. N.; Srivastava, P. K.; Brennan, M. F.
EJC Supplements (2003)

Fulltext@MSK | Save

Phase 1 study of CT-2106 (polyglutamate camptothecin) in patients with advanced malingnancies

Meeting Abstract

Sayid, S.; Dupont, J.; McNamara, M.; Doroshow, J. H.; Pezzulli, S.; Spriggs, D.; Eastham, E.; Stromatt, S.; Takimoto, C.
Clinical Cancer Research (2003)

Fulltext@MSK | Save

Initial treatment of mantle cell lymphoma with sequential radioimmunotherapy with Tositumomab/Iodine I131 I-Tositumomab followed by CHOP chemotherapy results in a high complete remission rate

Meeting Abstract

Zelenetz, A. D.; Donnelly, G.; Halaas, J.; Sgouros, G.; Humm, J.; Popplewell, L.; Reyes, S.; Maignan, K.; Campbell, C.; Moskowitz, C. H.; more...
Blood (2003)

Fulltext@MSK | Save

Pentostatin, cydophosphamide, and rituximab (PCR therapy): A new active regimen for previously treated patients with chronic lymphocytic leukemia (CLL)

Meeting Abstract

Weiss, M. A.; Lamanna, N.; Jurcic, J. G.; Maslak, P. G.; Vonhassel, M.; Horgan, D.; Scheinberg, D. A.; Gencarelli, A. N.
Blood (2003)

Fulltext@MSK | Save

Phase 1 dose escalating and pharmacokinetic (PK) study of KOS-862 (epothilone D): Phase 2 dose and schedule defined

Meeting Abstract

Spriggs, D.; Dupont, J.; Pezzulli, S.; Larkin, J.; Cropp, G.; Johnson, R.; Hannah, A. L.
Clinical Cancer Research (2003)

Fulltext@MSK | Save